Effect of hydrocortisone, methylprednisolone aceponate and momethasone furoate on collagen synthesis in human skin in vivo. 1997

K M Haapasaari, and J Risteli, and J Karvonen, and A Oikarinen
Department of Dermatology, University of Oulu, Finland.

BACKGROUND Topical corticoids decrease de novo collagen synthesis in the human skin. OBJECTIVE We studied the effect of three corticoids, hydrocortisone (HC), methylprednisolone aceponate (MPA) and momethasone furoate (MMF) on the de novo synthesis of type I and III collagens. METHODS Fifteen healthy male volunteers treated four areas marked on their abdominal skin for 1 week. HC was applied twice a day, MPA and MMF once a day plus vehicle once a day and vehicle twice a day. After the treatment, suction blisters were induced on the treated areas, the suction blister fluid (SBF) was collected and procollagen propeptides of type I and III procollagens (PINP, PIIINP, respectively) were analyzed by radioimmunological assays. The protein concentration in SBF was determined by a colorimetric method. RESULTS All the corticoids studied decreased the procollagen propeptide concentrations in SBF. HC decreased PINP concentration by 66%, MPA by 68% and MMF by 72%. HC decreased PIIINP by 62%, MPA by 68% and MMF by 72%. The protein concentration in SBF was decreased by 11-15% by these topical corticoids. CONCLUSIONS HC decreases the concentration of procollagen propeptides in human skin in males to nearly the same extent as MPA and MMF.

UI MeSH Term Description Entries
D008297 Male Males
D008775 Methylprednisolone A PREDNISOLONE derivative with similar anti-inflammatory action. 6-Methylprednisolone,Medrol,Metipred,Urbason,6 Methylprednisolone
D010446 Peptide Fragments Partial proteins formed by partial hydrolysis of complete proteins or generated through PROTEIN ENGINEERING techniques. Peptide Fragment,Fragment, Peptide,Fragments, Peptide
D011244 Pregnadienediols Doubly unsaturated pregnane derivatives with two hydroxy groups substituted anywhere on the rings or side chains. Dihydroxypregnadienes
D011347 Procollagen A biosynthetic precursor of collagen containing additional amino acid sequences at the amino-terminal and carboxyl-terminal ends of the polypeptide chains. Protocollagen,Procollagen Type M
D003094 Collagen A polypeptide substance comprising about one third of the total protein in mammalian organisms. It is the main constituent of SKIN; CONNECTIVE TISSUE; and the organic substance of bones (BONE AND BONES) and teeth (TOOTH). Avicon,Avitene,Collagen Felt,Collagen Fleece,Collagenfleece,Collastat,Dermodress,Microfibril Collagen Hemostat,Pangen,Zyderm,alpha-Collagen,Collagen Hemostat, Microfibril,alpha Collagen
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D006854 Hydrocortisone The main glucocorticoid secreted by the ADRENAL CORTEX. Its synthetic counterpart is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Cortef,Cortisol,Pregn-4-ene-3,20-dione, 11,17,21-trihydroxy-, (11beta)-,11-Epicortisol,Cortifair,Cortril,Epicortisol,Hydrocortisone, (11 alpha)-Isomer,Hydrocortisone, (9 beta,10 alpha,11 alpha)-Isomer,11 Epicortisol
D000068656 Mometasone Furoate A pregnadienediol derivative ANTI-ALLERGIC AGENT and ANTI-INFLAMMATORY AGENT that is used in the management of ASTHMA and ALLERGIC RHINITIS. It is also used as a topical treatment for skin disorders. Asmanex,Asmanex Twisthaler,Elocon,Mometasone,Mometasone Furoate Monohydrate,Nasonex,Rinelon,Sch 32088,Sch-32088,Furoate Monohydrate, Mometasone,Furoate, Mometasone,Monohydrate, Mometasone Furoate,Sch32088,Twisthaler, Asmanex
D000287 Administration, Topical The application of drug preparations to the surfaces of the body, especially the skin (ADMINISTRATION, CUTANEOUS) or mucous membranes. This method of treatment is used to avoid systemic side effects when high doses are required at a localized area or as an alternative systemic administration route, to avoid hepatic processing for example. Drug Administration, Topical,Administration, Topical Drug,Topical Administration,Topical Drug Administration,Administrations, Topical,Administrations, Topical Drug,Drug Administrations, Topical,Topical Administrations,Topical Drug Administrations

Related Publications

K M Haapasaari, and J Risteli, and J Karvonen, and A Oikarinen
February 1990, Arzneimittel-Forschung,
K M Haapasaari, and J Risteli, and J Karvonen, and A Oikarinen
March 1998, Journal of the European Academy of Dermatology and Venereology : JEADV,
K M Haapasaari, and J Risteli, and J Karvonen, and A Oikarinen
September 2007, Experimental dermatology,
K M Haapasaari, and J Risteli, and J Karvonen, and A Oikarinen
November 1976, The British journal of dermatology,
K M Haapasaari, and J Risteli, and J Karvonen, and A Oikarinen
January 1995, The British journal of dermatology,
K M Haapasaari, and J Risteli, and J Karvonen, and A Oikarinen
January 2006, International journal of clinical practice,
K M Haapasaari, and J Risteli, and J Karvonen, and A Oikarinen
January 1979, Archives of oral biology,
K M Haapasaari, and J Risteli, and J Karvonen, and A Oikarinen
June 1998, British journal of cancer,
K M Haapasaari, and J Risteli, and J Karvonen, and A Oikarinen
May 1993, Journal of the American Academy of Dermatology,
K M Haapasaari, and J Risteli, and J Karvonen, and A Oikarinen
November 1991, Nihon yakurigaku zasshi. Folia pharmacologica Japonica,
Copied contents to your clipboard!